Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fiberweb (India) Limited manufactures technical textiles and nonwoven fabrics primarily for hygiene, medical, and industrial applications across India and export markets. The company operates manufacturing facilities producing spunbond, meltblown, and composite nonwoven materials used in disposable hygiene products (diapers, sanitary napkins), medical protective wear, and industrial filtration. With 38% gross margins and minimal debt (0.04 D/E), the stock trades at 0.7x book value despite 106% net income growth, suggesting market skepticism about sustainability of recent margin expansion.
Fiberweb operates capital-intensive spunbond and meltblown production lines that convert polypropylene resin into specialized nonwoven fabrics. Revenue comes from selling rolls of technical fabrics to converters (who make finished hygiene products) and industrial customers. Pricing power derives from technical specifications (basis weight, tensile strength, barrier properties) and customer qualification cycles that create switching costs. The 38% gross margin reflects polymer input costs (60-65% of COGS), energy consumption, and production efficiency. Recent 106% net income growth likely reflects operating leverage from capacity utilization improvements and favorable polymer spreads rather than pricing power.
Polypropylene resin prices - primary raw material cost (60-65% of COGS), directly impacts gross margins with 1-2 quarter lag for contract pass-through
Hygiene product demand growth in India - driven by urbanization, female workforce participation, and disposable income growth affecting diaper/sanitary napkin penetration rates
Capacity utilization rates - with high fixed costs, moving from 70% to 85% utilization can expand operating margins by 300-500 basis points
Export competitiveness - rupee depreciation versus dollar/euro improves export margins for medical and industrial nonwovens sold to developed markets
Commodity input cost volatility - polypropylene prices swing 30-40% based on crude oil and naphtha costs, with imperfect pass-through creating margin compression risk during rapid increases
Technology disruption - shift toward sustainable/biodegradable nonwovens (PLA, cellulose-based) could obsolete polypropylene-based capacity if environmental regulations tighten or consumer preferences shift
China overcapacity - Chinese nonwoven manufacturers operate at massive scale with lower costs, posing dumping risk in export markets and price pressure in India if import duties ease
Domestic capacity additions - Indian hygiene market growth attracting new entrants and expansions from established players (Grasim, Avgol India), risking oversupply and price competition
Backward integration by customers - large hygiene product manufacturers (P&G, Kimberly-Clark, local brands) may invest in captive nonwoven capacity to secure supply and capture margins
Limited differentiation - nonwovens are semi-commoditized with specifications-based competition, reducing pricing power except for specialized medical/filtration grades
Negative free cash flow despite profitability - $0.2B capex on $0.1B operating cash flow indicates aggressive expansion that could strain liquidity if demand disappoints or project delays occur
Working capital intensity - 3.72x current ratio includes substantial inventory (polymer resin, finished goods), vulnerable to obsolescence or price declines if demand slows
moderate - Hygiene nonwovens (50-60% of revenue) are relatively non-cyclical as diapers and sanitary products are necessities with stable demand. However, industrial nonwovens (15-20%) tied to construction, automotive, and manufacturing are cyclically sensitive. Medical segment benefited from COVID-related PPE demand but faces normalization. Overall sensitivity is dampened by India's structural growth in hygiene product penetration (currently 10-15% diaper penetration versus 95%+ in developed markets), which provides secular tailwind independent of GDP cycles.
Moderate sensitivity through two channels: (1) Minimal direct impact given 0.04 debt/equity ratio and strong balance sheet - interest expense is negligible. (2) Indirect impact through customer demand - rising rates in India could slow consumer discretionary spending and delay hygiene product adoption among price-sensitive middle-class consumers. Higher rates also increase cost of capital for capacity expansion, though current 3.72x current ratio provides internal funding cushion. Valuation multiple compression risk exists as 0.7x P/B suggests market already discounts growth.
Minimal - Company maintains 3.72x current ratio and 0.04 debt/equity, indicating negligible reliance on credit markets for operations or growth. Customer credit risk exists in B2B sales to hygiene product converters, but 90-day receivables cycle is standard for industrial textiles. Supplier financing for polypropylene resin purchases may tighten during credit stress, but strong balance sheet provides negotiating leverage.
value - Stock trades at 0.7x book value and 6.0x EV/EBITDA despite 106% net income growth, attracting deep value investors betting on mean reversion or re-rating. The -3.3% FCF yield and high capex intensity deter income-focused investors. Recent 106% earnings growth creates momentum interest, but -0.3% one-year return suggests skepticism about sustainability. Suitable for investors with 2-3 year horizon betting on India hygiene market structural growth and operating leverage from capacity utilization improvements.
moderate-to-high - Small-cap Indian textile manufacturer with $1.3B market cap faces liquidity constraints and sensitivity to commodity cost swings. 14.6% three-month gain followed by -9.8% six-month decline indicates episodic volatility around earnings and polymer price moves. Estimated beta of 1.2-1.4x versus Indian equity indices given cyclical industrial exposure and small-cap liquidity premium.
